Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Thyroid Carcinoma, Anaplastic × Adalimumab × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Endocrine 1

Conditions

Thyroid Carcinoma, Anaplastic 1

Interventions

trametinib 9 dabrafenib 9 Paclitaxel 9 pembrolizumab 4 fosbretabulin 4 lenvatinib 3 Sorafenib 3 Radiotherapy, Intensity-Modulated 3 efatutazone 2 combretastatin 2 cobimetinib 2 atezolizumab 2 aldesleukin 2 Vemurafenib 2 Trastuzumab 2 Radiotherapy 2 Gefitinib 2 Filgrastim 2 Everolimus 2 Doxorubicin 2 Docetaxel 2 Cisplatin 2 Carboplatin 2 zimberelimab 1 vandetanib 1 tumor necrosis factor-alpha, CNGRC fusion protein, human 1 tremelimumab 1 tislelizumab 1 tipifarnib 1 surufatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02516774 2016-01-26

TAM-RT

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1 Withdrawn

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡